LAB vs. TXG, TRNS, CTKB, BNGO, SENS, EYPT, ALNT, QTRX, AEHR, and QSI
Should you be buying Standard BioTools stock or one of its competitors? The main competitors of Standard BioTools include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Bionano Genomics (BNGO), Senseonics (SENS), EyePoint Pharmaceuticals (EYPT), Allient (ALNT), Quanterix (QTRX), Aehr Test Systems (AEHR), and Quantum-Si (QSI). These companies are all part of the "measuring and control equipment" industry.
Standard BioTools vs.
Standard BioTools (NASDAQ:LAB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
10x Genomics received 50 more outperform votes than Standard BioTools when rated by MarketBeat users. However, 100.00% of users gave Standard BioTools an outperform vote while only 51.89% of users gave 10x Genomics an outperform vote.
In the previous week, 10x Genomics had 6 more articles in the media than Standard BioTools. MarketBeat recorded 7 mentions for 10x Genomics and 1 mentions for Standard BioTools. Standard BioTools' average media sentiment score of 0.75 beat 10x Genomics' score of 0.59 indicating that Standard BioTools is being referred to more favorably in the media.
10x Genomics has a net margin of -28.93% compared to Standard BioTools' net margin of -79.92%. 10x Genomics' return on equity of -25.07% beat Standard BioTools' return on equity.
53.7% of Standard BioTools shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 53.1% of Standard BioTools shares are owned by company insiders. Comparatively, 10.0% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Standard BioTools has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Standard BioTools, indicating that it is currently the more affordable of the two stocks.
Standard BioTools has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.
Standard BioTools currently has a consensus target price of $2.88, suggesting a potential upside of 96.92%. 10x Genomics has a consensus target price of $23.86, suggesting a potential upside of 65.56%. Given Standard BioTools' stronger consensus rating and higher possible upside, research analysts clearly believe Standard BioTools is more favorable than 10x Genomics.
Summary
Standard BioTools beats 10x Genomics on 10 of the 19 factors compared between the two stocks.
Get Standard BioTools News Delivered to You Automatically
Sign up to receive the latest news and ratings for LAB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Standard BioTools Competitors List
Related Companies and Tools
This page (NASDAQ:LAB) was last updated on 2/5/2025 by MarketBeat.com Staff
